Humanized Mouse and Rat Model Market: Current Trends and Future Opportunities

Humanized Mouse and Rat Model Market

Humanized Mouse and Rat Model Market Humanized Mouse and Rat Model Market

PUNE, India, 2020-Aug-04 — /EPR Network/ —

According to the new market research report “Humanized Mouse and Rat Model Market by Type (Genetic, Cell-Based (CD34, PBMC, BLT)), Application (Neuroscience, Hematopoesis, Oncology, Immunology & Infectious Diseases) & End User (Pharmaceutical & Biotechnology Companies, CRO)) – Global Forecast” published by MarketsandMarkets™.

How Key Factors will Drives the Market Growth?

The Humanized Mouse Models Market is projected to reach USD 128.9 Million, at a CAGR of 9.9% during the forecast period. The Humanized Rat Models Market is expected to reach USD 8.9 Million, at a CAGR of 8.4% during the forecast period.

By application, the market is categorized into oncology, immunology and infectious diseases, neuroscience, hematopoiesis, toxicology, and other applications. Of all these application segments, oncology accounted for the largest share of the market. The increasing research activities and growing funding from various governments to carry out research studies on cancer are the major factors driving the growth of this segment.

By type, the humanized mouse models market is categorized into genetic and cell-based humanized mouse models. The cell-based humanized mouse models segment is expected to grow at the highest CAGR during the study period. The high growth of this segment can be attributed to the growing applications of cell-based humanized mouse models.

Browse 94 market data Tables and 42 Figures spread through 189 Pages and in-depth TOC – Request Research Sample Pages:

Humanized Mouse and Rat Model Market

Humanized Mouse and Rat Model Market

Humanized Mouse and Rat Model Market Dynamics:

Opportunity: Increased production of monoclonal antibodies

With personalized medicine gaining in importance, monoclonal antibodies (mAbs) showcase an enormous potential to treat a wide range of diseases. This is a positive indicator for market growth as mouse models are extensively used in the production of mAbs. Researchers have replaced few parts of mouse antibodies with human components; the final antibodies with a mixture of human and mouse components are known as chimeric antibodies. Some monoclonal antibodies are now entirely human as a larger portion of the human component is engrafted in the mouse antibody.

Driver: Growing demand for personalized medicine

Personalized medicine is the process of developing tailored medicines to target individualized treatment and care based on personal and genetic variations. These medicines are designed through the use of animal models, particularly mice models. Immune-deficient models are transplanted with human tissues and the disease expressed is recorded. This is followed by treating the model with a whole series of drugs or gene therapies to find the most suitable treatment, thus generating suitable or personalized medicine for patients.

Currently, cancer is a major burden on the healthcare systems across geographies. By 2020, the direct/indirect cost of cancer is estimated to be USD 300 billion in the US. Several in vitro and in vivo strategies are being developed in an attempt to combat the rising prevalence of cancer and offer effective treatments to patients.

Download PDF Brochure:

North America dominated the global humanized mouse models market. Growth in this regional segment can be attributed to the increasing monoclonal antibody production, preclinical activities by CROs and pharmaceutical R&D, continued and responsible use of animals ensured by animal care organizations, growing biomedical research in the US along with government support for the development of protein drugs, and growing stem cell research in Canada.

The major market players in the humanized mouse models market include The Jackson Laboratory (US), Taconic Biosciences, Inc. (US), Horizon Discovery Group plc (UK), genOway, S.A. (France), Charles River Laboratories (US), Harbour Antibodies BV (China), Hera BioLabs (US), Vitalstar Biotechnology Co., Ltd. (China), inGenious Targeting Laboratory (US), AXENIS S.A.S (France), Crown Bioscience, Inc. (US), Transgenic, Inc. (Japan), and Champions Oncology, Inc. (US). The major players in the humanized rat models market include Horizon Discovery Group plc (UK), Hera BioLabs (US), and Yecuris Corporation (US).

Matched content

Editor’s pick

Do NOT follow this link or you will be banned from the site!